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cancer globally.
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Lay summary
Non-alcoholic fatty liver disease and non-
alcoholic steatohepatitis can lead to
advanced liver disease. Both conditions
are becoming increasingly prevalent as
the epidemics of obesity and diabetes
continue to increase. A mathematical
model was built to understand how the
disease burden associated with non-
alcoholic fatty liver disease and non-
alcoholic steatohepatitis will change over
time. Results suggest increasing cases of
advanced liver disease and liver-related
mortality in the coming years.Genetic and Metabolic Diseases. This is an open access article under the CC BY-NC-ND
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Background & Aims: Non-alcoholic fatty liver disease (NAFLD)
and non-alcoholic steatohepatitis (NASH) are increasingly a
cause of cirrhosis and hepatocellular carcinoma globally. This
burden is expected to increase as epidemics of obesity, diabetes
and metabolic syndrome continue to grow. The goal of this anal-
ysis was to use a Markov model to forecast NAFLD disease bur-
den using currently available data.
Methods: A model was used to estimate NAFLD and NASH dis-
ease progression in eight countries based on data for adult
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prevalence of obesity and type 2 diabetes mellitus (DM).
Published estimates and expert consensus were used to build
and validate the model projections.
Results: If obesity and DM level off in the future, we project a
modest growth in total NAFLD cases (0–30%), between 2016–
2030, with the highest growth in China as a result of urbaniza-
tion and the lowest growth in Japan as a result of a shrinking
population. However, at the same time, NASH prevalence will
increase 15–56%, while liver mortality and advanced liver dis-
ease will more than double as a result of an aging/increasing
population.
Conclusions: NAFLD and NASH represent a large and growing
public health problem and efforts to understand this epidemic
and to mitigate the disease burden are needed. If obesity and
DM continue to increase at current and historical rates, both
NAFLD and NASH prevalence are expected to increase. Since018 vol. 69 j 896–904
was estimated with adjustment for all-cause mortality (includ-
ing general background mortality, excess cardiovascular mortal-
JOURNAL 
OF HEPATOLOGYboth are reversible, public health campaigns to increase aware-
ness and diagnosis, and to promote diet and exercise can help
manage the growth in future disease burden.
Lay summary: Non-alcoholic fatty liver disease and non-
alcoholic steatohepatitis can lead to advanced liver disease.
Both conditions are becoming increasingly prevalent as the epi-
demics of obesity and diabetes continue to increase. A mathe-
matical model was built to understand how the disease
burden associated with non-alcoholic fatty liver disease and
non-alcoholic steatohepatitis will change over time. Results
suggest increasing cases of advanced liver disease and liver-
related mortality in the coming years.
 2018 European Association for the Study of the Liver. Published by
Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Non-alcoholic fatty liver disease (NAFLD) is a leading cause of
liver disease globally.1–3 This condition is characterized by
excess liver fat in the absence of other causes such as alcohol
consumption.4,5 Obesity, type 2 diabetes mellitus (DM) and
metabolic syndrome are consistently identified as the most
important risk factors for NAFLD.4,6
In order to classify the population, NAFLD may be divided
into two groups: NAFL (steatosis only) or non-alcoholic steato-
hepatitis (NASH), where steatosis is accompanied by inflamma-
tion and ballooning. NASH frequently progresses to liver
fibrosis,7 which is the main risk factor for liver-related mortal-
ity. 8 Odds of progression to advanced liver disease, including
hepatic decompensation and hepatocellular carcinoma (HCC),
are higher among those with NASH compared to those with
NAFL.7 Increasing age, obesity, DM and the presence of NASH
have been consistently identified as risk factors for progression
to cirrhosis.6,9
There is an ongoing need to better define the current and
future burden of NAFLD-related liver disease. Modeling can be
used as a tool to take into account existing epidemiology
parameters to forecast disease burden. Several recent analyses
assessed the disease and economic burden associated with
NASH.10–12 Prior studies were based on existing data reported
in the literature, but such studies are confounded by varying
case definitions, diagnostic techniques, and staging used for
NAFLD/NASH; as well as relatively small and varying sample
populations. Furthermore, most studies do not quantify disease
regression, which can occur spontaneously in the disease
course.7 A recently developed dynamic model of NAFLD over-
comes several of these limitations.13 In this analysis, we report
the results of such a model across multiple regions.
Materials and methods
Model
The Markov model was built for China, France, Germany, Italy,
Japan, Spain, UK and US. The selection of countries was based
on the availability of data, the willingness of the national
experts to collaborate, and our capacity to conduct parallel anal-
yses. These countries represent regions with varying levels of
risk factors for NAFLD development. Fibrosis progression rates
were back-calculated based on surveillance data, and they were
adjusted for the level of obesity in each country (see details in
the supplementary information). Progression to advanced liver
Journal of Hepatology 2disease (HCC or decompensated cirrhosis) and liver-related
death were based on published estimates (Tables S3 and
S4).13 A literature search was performed to identify reported
estimates of NAFLD/NASH prevalence and incidence, including
reports of late stage disease (e.g. HCC attributed to NAFLD/
NASH) (Table S2). National estimates for adult prevalence of
obesity (body mass index [BMI] ≥25 kg/m2 for China and Japan;
BMI ≥30 kg/m2 for other countries) and DM were also used in
the analysis to estimate underlying trends in NAFLD incidence
(Table S2). In addition to the literature search, a Delphi process
was used in which experts from each country were interviewed
to identify critical modeling inputs and review model outputs
against estimates of disease burden (Table S1). Input data were
typically collected during different time frames, so modeling
was used to calibrate to reported years of data collection. The
model tracked each country’s NAFLD population by fibrosis
stage and NASH status (steatosis only or NASH). Progression
of disease through fibrosis and liver disease stages (Fig. S1)ity, and liver-related mortality).
For each model, uncertainty intervals were defined for key
uncertain inputs including total NAFLD prevalence, excess car-
diovascular mortality multipliers, and fibrosis transition proba-
bilities (Table S4). For all uncertain inputs, Beta-PERT
distributions were used.14 Monte Carlo simulation and sensitiv-
ity analysis were conducted using an Excel add-in (Crystal
Ball 11.1.3708.0 by Oracle) to estimate 95% uncertainty inter-
vals (Fig. S3). The sensitivity analysis was conducted to identify
the inputs that accounted for the greatest variation in modeled
outcomes.
New NAFLD cases
For the countries studied, accurate longitudinal estimates of
NAFLD incidence were either unavailable or were limited to
special populations. Therefore, annual changes in the number
of new cases were back-calculated based on trends for adult
prevalence of obesity and DM as described in the supplemen-
tary information (Fig. S2).
Prevalence
There are varied estimates of NAFLD prevalence in the general
population. A reported 17–51% of adults have NAFLD,4,15–18
while a meta-analysis of studies from 2006–2014 estimated
NAFLD prevalence of 24% (20–29%) in the general popula-
tion,10 largely based on studies of populations in Western
countries.
Based on a data review and the Delphi process described,
input prevalence values were entered in the models. It was
assumed that 25% of individuals aged ≥15 years in 2015 experi-
enced NAFLD in France, Germany, Spain and the UK. For the
Italy model, it was assumed that 25% of the population (all ages)
experienced NAFLD, equivalent to 28% prevalence among per-
sons aged ≥15 years. In China and Japan, there was a starting
NAFLD prevalence rate of 20% among individuals aged ≥15
years, equivalent to 17% among all ages. For the US model, a
starting prevalence of 30% among the population aged ≥15 years
in 2015 was the assumption.
For the age and gender distribution of the NAFLD population,
data from national studies were used, when available18–20
(Table S2). For countries without general population prevalence
distributions, it was assumed that overall prevalence among
018 vol. 69 j 896–904 897
males was 30% higher than in females, with prevalence rates
increasing with age. As prevalence studies typically did not
include children, it was assumed that prevalence would decline
among the youngest age groups not included in prevalence esti-
mates. Given that childhood dietary patterns are correlated with
later development of NAFLD,21–23 obesity among pediatric pop-
ulations was assumed to increase with age.
NASH status
The NAFLD population was classified within the model as NAFL
(steatosis only) or NASH. The prevalence of NASH was based on
reported figures, in addition to time- and age- dependent fibro-
sis progression modeling. It was assumed that up to 5% of
NAFLD cases without NASH could be NASH regressors, with
most NASH regressors having no fibrosis (F0 stage). Therefore,
a relatively small number of fibrotic cases (F1-F4) were classi-
fied as non-NASH NAFLD. The vast majority of modeled fibrotic
cases (F1-F4) were assumed to be NASH.
Reported estimates state that 3–5% of adults have
NASH.4,16,24,25 The model for the US assumed that approxi-
mately 20% of NAFLD cases would be classified as NASH in
2015.26–28 Fibrosis progression rates and NASH status were first
calibrated to US data and then extrapolated to other countries
with adjustment for varying levels of overweight and obesity.6
Due to demographic factors,29 in addition to rates of overweight
and obesity, the proportion of NASH cases varied between coun-
tries, with overall aging of the population associated with an
increased proportion of NASH cases among the total NAFLD
population. For distribution by fibrosis score, the US model
was calibrated to the assumption that approximately 20% of
NASH cases would be classified as ≥F3 in 2015.30
Mortality
For each country, background mortality rates by age and gender
were based on historical and medium fertility variant projected
estimates for total deaths from the United Nations population
database29 divided by population estimates by age group and
29
(Table S1). Analyses of transplants from the European
Liver Transplant Registry demonstrated that NAFLD may be
under-recognized as an indicator for liver transplant, with many
transplants classified simply as cirrhosis or HCC.36 Studies of
transplant recipients in Sweden and Germany report that over
40% of cases classified as cryptogenic cirrhosis were NASH-
related37 and NASH was the third leading cause of HCC resulting
in transplantation.38 In the US, there is evidence that numerous
transplants indicated for cryptogenic or idiopathic cirrhosis are
NAFLD-related based on obesity rates in this population.39,40 As
changes occur to the transplantation system in China, there will
be uncertainty surrounding the future availability of donated
livers.41–43 Given the uncertainties around transplant demand
and availability, it was assumed that the annual number of
NAFLD-related transplants would remain constant through
2030. This is a conservative estimate as data already suggest
that the proportion of transplants attributable to NAFLD is
increasing.40
Results
NAFLD population
Total prevalent NAFLD case estimates ranged from 10.53 M
(Spain) to 243.67 M (China) in 2016 (Fig. 1). While China was
estimated to have the greatest number of cases, the estimated
prevalence of NAFLD was lower than the other countries at
17.6% (all ages) (Table 1). The highest overall 2016 rate
(26.3%) was estimated for the US. By 2030, the total NAFLD pop-
ulation was projected to increase by 18.3% to 100.9 million
cases, with prevalence of 28.4%. In the European countries, the
estimated NAFLD population in 2016 ranged from 18.45 M cases
(Germany) to 10.53 M cases (Spain). By 2030, the number of
cases had increased most in the UK (20.2%; from 14.08 M cases
in 2016 to 16.92 M cases in 2030), while the number of cases
increased least in Germany (13.5% increase from 18.45 M cases
in 2016 to 20.95 M cases in 2030). By 2030, the highest preva-
lence was estimated in Italy (29.5%) and the lowest in France
Research Article Genetic and Metabolic Diseasesgender from the same database. Background rates were
adjusted to account for incremental increases in mortality
related to cardiovascular disease (CVD). A range of estimates
have been reported for excess mortality among patients with
NAFLD, with some studies demonstrating little increase and
others suggesting that cardiovascular mortality is significantly
elevated compared to the non-NAFLD population.31–34 A stan-
dard mortality ratio of 1.15 was applied to all background mor-
tality rates in all years of the model with an input range of 1.00
(background mortality rates with no adjustment) to 1.3133 for
uncertainty analysis. While excess CVD mortality may increase
with NAFLD severity, data for this are sparse and a constant
multiplier was applied to all stages of disease. Liver-related
mortality is markedly increased in the NASH population35 and
was calculated separately as part of the liver disease progres-
sion modeling (Tables S3 and S4). Liver-related deaths were
modeled as a function of HCC, decompensated cirrhosis, and
liver transplant populations.
Transplants
Annual liver transplantations by country were reported by the
European Liver Transplant Registry and by country-specific
reporting entities, including the China Liver Transplant Registry
and US Organ Procurement and Transplantation Network898 Journal of Hepatology 2(23.6%). The greatest overall and relative increase in NAFLD
prevalence was estimated for China, where cases were esti-
mated to increase 29.1% from 246.33 M cases in 2016 to
314.58 M NAFLD cases in 2030. Of the countries studied, China
had the largest relative rate increase over the time period to
22.2%. The largest number of prevalent cases was estimated
for the cohort of 55–59 year olds followed by the cohort of
50–54 year olds, with these groups comprising over 20% of
model cases in 2016 (Fig. S4).
Results of the uncertainty analysis showed the potential
range of NAFLD cases for each country based on the uncertainty
around key inputs (Fig. S3). For each country, uncertainty sur-
rounding NAFLD prevalence estimates in the general population
were the key driver of model uncertainty, followed by the range
of standard of mortality ratios for increased risk of CVD. When
considering forecasted uncertainty around prevalence in 2030,
the input general prevalence rate and standard mortality ratio
together accounted for over 95% of modeled uncertainty.
NAFL population
The NAFL population was defined as individuals with simple
steatosis who have never progressed to NASH, or a relatively
small number of cases who were formerly NASH and experi-
enced disease regression. Nearly all cases were estimated to018 vol. 69 j 896–904
be F0 with a small number of fibrotic cases related to regressed
NASH. The NAFL population was estimated to increase most in
China (26.2%; from 211.05 M cases in 2016 to 266.32 M case
in 2030), and least in Germany (7.2%; from 15.12 M cases to
16.21 M cases). In Japan, the NAFL population decreased by
2.6% from 18.90 M cases in 2016 to 18.41 M cases in 2030
(Fig. 1).
When considering only fibrotic NAFL cases (≥F1), Japan was
estimated to have the smallest increase in this population with
24,310 ≥F1 NAFL cases in 2016 increasing 13% to 27,455 cases in
2030, while the combined cirrhotic and HCC NAFL population
increased by 65% from 310 to 510 cases. The greatest increase
in the ≥F1 NAFL population was estimated in China where cases
increased 51% from 202,470 in 2016 to 304,990 in 2030. The
greatest increase in the combined cirrhotic and HCC population
was observed in France where cases increased 159% from 190 to
490 cases.
NASH population
Total cases in 2016 were estimated to be most numerous in
China (32.61 M cases), but the proportion classified as NASH
was the lowest (13% of total NAFLD) of the studied countries,
potentially reflecting a more recent onset of the obesity and
diabetes epidemics (Fig. 2). By 2030, the NASH population
in China was projected to increase 48% to 48.26 M cases, or
15% of all NAFLD cases. In the five European countries, total
NASH cases in 2016 ranged from 1.80 M (Spain) to 3.33 M
(Germany). Increases during 2016–2030 ranged from 43%
(Germany) to 49% (Spain), and the most numerous cases in
2030 were estimated in Germany (4.74 M). The proportion
of total NAFLD cases classified as NASH in 2016 ranged from
16% (France) to 18% (UK). By 2030, the proportion ranged
from 21% (France) to 23% (Germany). In the US, the relative
increase in NASH cases was estimated at 56%, increasing from
17.32 M cases (2016) to 27.00 M cases (2030). Among NASH
cases in 2016, an estimated 21% in the US had F3/F4 fibrosis
or advanced liver disease, encompassing approximately 3.55
M cases (Fig. 2). By 2030, this number increased at a greater
rate than other studied countries (124%) to 7.94 M cases,
accounting for 29% of all NASH cases. Japan had the smallest
estimated increase in these cases from 665,970 cases in 2016
to 990,850 cases in 2030 (49% increase). In 2016, the highest
proportion of NASH cases in advanced disease states was esti-
mated in Italy (22%) while the smallest was in China (12%).
By 2030, the highest proportion was observed in Spain where
792,110 individuals (29.5%) were estimated to have NASH-
related advanced disease and the lowest was China with
7,942,280 cases (16.5%). In every country studied, increases
NASH
NAFL
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Fig. 1. Distribution of NAFLD population by fibrosis stage – 2016 & 2030. NAFLD, non-alcoholic fatty liver disease.
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China France Germany
2016 Country population (000) 1,382,300 64,700 80,700
2030 Country population (000) 1,415,500 68,000 79,300
Adult obesity prevalence (BMI) ≥25 kg/m2 ≥30 kg/m2 ≥30 kg/m
2016 26.9% 15.9% 25.2%
2030 28.4% 17.7% 26.1%
NAFLD
2016 Total cases 243,661,000 13,982,000 18,447,000
2016 Prevalence (all ages) 17.6% 21.6% 22.9%
2030 Total cases 314,580,000 16,046,000 20,945,000
2030 Prevalence (all ages) 22.2% 23.6% 26.4%
NAFL
2016 Total cases 211,049,000 11,676,000 15,122,000
2016 Prevalence (all ages) 15.3% 18.1% 18.7%
2030 Total cases 266,318,000 12,657,000 16,206,000
2030 Prevalence (all ages) 18.8% 18.6% 20.4%
NASH
2016 Total cases 32,612,300 2,305,800 3,325,400
2016 Prevalence (all ages) 2.4% 3.6% 4.1%
2030 Total cases 48,262,200 3,388,900 4,739,000
2030 Prevalence (all ages) 3.4% 5.0% 6.0%
Incident NAFLD
2016 Total cases 10,139,100 467,600 513,200
2016 Prevalence (all ages) 7.3 7.2 6.4
2030 Total cases 10,348,100 347,900 479,500
2030 Prevalence (all ages) 7.3 5.1 6.0
NASH mortality
2016 Total cases 25,580 2,490 5,180
2016 Prevalence (all ages) 103,840 5,460 8,350
2030 Total cases 55,740 7,030 12,510
2030 Prevalence (all ages) 163,920 9,890 13,660
BMI, body mass index; NAFL, non-alcoholic fatty liver; NASH, non-alcoholic steatoh
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Fig. 2. Distribution of NASH population by fibrosis stage – 2015 & 2030. NAS
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59,800 126,600 46,100 64,200 324,100
59,100 120,600 45,900 68,600 355,800
≥30 kg/m2 ≥25 kg/m2 ≥30 kg/m2 ≥30 kg/m2 ≥30 kg/m2
10.9% 23.9% 18.0% 26.9% 39.6%
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OF HEPATOLOGYin the number of advanced fibrosis cases in the NASH popu-
lation were larger than increases in earlier fibrosis stages.
Cirrhosis and end-stage disease
The number of NAFLD cases with compensated cirrhosis and
end-stage disease is projected to increase in every country.
The smallest increase (64%) was projected for Japan where
prevalent cases increase from 127,840 to 282,670 during
2016–2030, and the largest percentage increase was expected
in France where cases increase 156% from 104,290 to 267,440
cases.
Prevalent decompensated cirrhosis was projected to show
the highest percentage increase in France from 11,560 cases in
2016 to 33,180 cases in 2030 (187% increase), followed by the
US where cases increase from 144,210 to 376,140 cases, a
161% increase. The smallest increase was projected in Japan
where cases increase 75% from 21,070 to 36,830 cases during
2016–2030.
In the US, incident decompensated cirrhosis is modeled to
increase by 150%, from 42,220 cases in 2016 to 105,430 cases
in 2030, while cumulative incidence during 2016–2030 was
estimated at 1,062,430 cases (Fig. 3). Among the European
countries, cumulative incidence of decompensated cirrhosis
ranged from 92,510 cases (France) to 171,030 cases (Germany),
while cumulative incidence in China was estimated at 751,190
cases. The greatest relative increase in incident decompensated
cirrhosis was observed in France where cases increase 164%
from 3,500 cases (2016) to 9,250 cases (2030), while the small-
est increase was estimated for Japan where cases increase 67%
during 2016–2030 from 5,870 to 9,780 cases.
In all countries, prevalent HCC cases related to NAFLD are
estimated to increase, ranging from increases of 47% in Japan
(2,200 cases in 2016 increasing to 3,240 cases in 2030) to
130% in the US (10,820 increasing to 24,860 cases). China had
the greatest number of prevalent HCC in all years, increasing
86% from 14,090 cases (2016) to 26,240 cases (2030). Among
the European countries, estimated increases during 2016–
2030 in prevalent HCC ranged from 93% (UK) to 125% (France)
during 2016–2030. The largest number of prevalent HCC cases
in 2016 and 2030 was estimated for Germany with 1,970 and
4,090 cases, respectively.
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Fig. 3. Incident decompensated cirrhosis, HCC and liver-related deaths amo
NAFLD, non-alcoholic fatty liver disease.Journal of Hepatology 2By 2030, China was projected to have the most incident HCC
cases (12,780 cases), an increase of 82% from 2016 (7,000 cases)
(Fig. 3). Japan experienced the smallest increase (44%), from
1,050 to 1,520 cases annually. In the US, incident HCC cases
increase by 122% during 2016–2030 from 5,510 to 12,240 cases.
In Europe, France was projected to have the largest increase
(117%) in incident HCC cases from 560 to 1,200 cases annually,
while the UK had the smallest increase (88%) from 850 to 1,600
cases annually.
Liver-related mortality
Liver-related deaths in 2016 ranged from 2,490 (France) to
30,240 (US) (Fig. 3). By 2030, China surpasses the US and is fore-
casted to have the largest number of liver-related deaths
(103,840 deaths) and Spain the fewest (4,530 deaths). The rela-
tive increase in annual liver deaths was greatest in France,
increasing 182% from 2,490 to 7,030 deaths, and the smallest
increase was in Japan, where liver deaths increased 73% from
4,720 to 8,130 deaths annually (Fig. 3).
Discussion
This study presents results from dynamic Markov modeling of
the burden of NAFLD-related disease in eight countries,
comprising over one-quarter of the total world population.29
A number of inputs included in national reports were used to
design and validate the models, along with both a review of
the literature and expert opinion on trends in disease preva-
lence and transition to more advanced disease states. For all
countries, as the national obesity prevalence grows at slower
rates and levels off, it is estimated that the prevalence of NAFLD
will follow a similar pattern with a five-year delay (Fig. S2). The
proportion of individuals with NASH among the NAFLD popula-
tion is forecasted to increase in the coming decades due to an
aging population and the projected rising prevalence of DM
among an aging population. These projections hold even if adult
obesity prevalence does not increase substantially from its
already high levels, since there is an approximate 10–15 year
delay between the change in obesity and DM. The proportion
of diabetic individuals with NASH is higher than that in a gen-
eral obese population;10,18,44 thus, we estimate that the total
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ing decades.
China has the youngest median age of all countries studied.
This implies relatively lower rates of advanced liver disease in
the near term and forecasted large increases in disease burden
in the coming decades (Fig. S3) as the population ages. In China,
increases in obesity and diabetes in the general population did
not begin on a large scale until decades after the US and Europe.
This means that the greatest impact in terms of advanced liver
disease and mortality will occur later, compared to Western
countries. If obesity levels continue to increase in China up to
the level observed in the US currently (about 30% of adults are
obese [≥30 BMI]), then the disease burden would be even higher
in China than shown here. The lifestyle and genetic factors that
cause diabetes and NAFLD begin at a lower BMI, in China and
Japan, compared to Caucasians.45–47The results of this modeling can inform public health care
systems about the coming disease burden associated with
NAFLD and NASH. Effective strategies are needed to prevent
and treat NASH in order to avert marked increases in the inci-
dence of end-stage liver disease and related mortality. Since
NAFLD is reversible, treatment can include diet and exercise
programs. A future with increasing disease burden is supported
by recent data demonstrating the growing contribution of NASH
toward demand for liver transplantation.1,40 NAFLD is increas-
ingly identified as an etiology of chronic liver disease in
Europe.48 In North America, NASH has been identified as the
second leading etiology for HCC cases requiring liver transplan-
tation.49 Given the expense associated with transplantation,50
limitations in organ supply,51 and the prevalence of multiple
co-morbidities that preclude transplantation, the procedure is
not a feasible solution to NASH-related outcomes at either the
global or national levels.52 Another notable result is the rapid
projected increase in individuals with cirrhosis, especially
decompensated cirrhosis that is cost and resource-
intensive.53–55 Increased incidence of decompensated cirrhosis
would be expected to have a proportionate impact on health-
care resources and costs associated with advanced liver dis-
ease,55,56 and magnify the negative consequences of increasing
disease burden.
NAFLD is now reported as the principal etiology contributing
to the incidence of HCC in North America,1 while the proportion
of HCC attributed to NAFLD is growing rapidly in Europe.57 The
growing burden of NAFLD will lead to further increases in inci-
dence of HCC. Many incident HCC cases are not diagnosed until
they have progressed to a stage where the most effective treat-
ment options, including liver transplantation, are not an
option.58 Interventions that slow the progression of NAFLD-
related liver disease have the potential to reduce the number
of incident liver cancer and related mortality.
The strength of the current analysis is the forecasted mortal-
ity among NAFLD cases: excess cardiovascular-related and
NASH liver-related mortality. There will clearly be a marked
increase in liver-related mortality in those afflicted by NASH.
A critical factor that is likely to drive the increase in NASH-
related mortality is the increased number and proportion of
individuals who will have cirrhosis within the growing NASH
population over time. This is linked to both the aging of the pop-
ulation, a known risk factor for having more advanced disease6
and the natural progression of the disease toward more
advanced stages of NASH.4,7 Importantly, in this study, the
spontaneous regression estimates from published literature
902 Journal of Hepatology 2were applied to generate the most accurate projections for dis-
ease progression possible. It highlights the need to identify
NAFLD cases, particularly those who have already developed
clinically significant fibrosis and target them for therapy. While
the model adjusted for the greater current magnitude of obesity
and DM, there have been dramatic increases in childhood obe-
sity60 and the onset of DM at younger ages is expected,61 sug-
gesting a longer course of disease with a potentially greater
risk of developing end-stage liver disease.
A limitation of this model, and all NAFLD modeling, is a
dearth of general population studies measuring hepatic steato-
sis using consistent methods. Furthermore, some estimates are
based on data collected several years ago,18 and likely do
not reflect the true burden of disease, given recent increases
in obesity and DM. Most population-based methods used ultra-
sound for NAFLD screening, which only reliably detects steatosis
of >20%.5 Greater uncertainty surrounds the NASH diagnosis
where classification of cases based on histology is challenging,
with relatively weak inter-observer agreement for some param-
eters, such as hepatocellular ballooning and fibrosis.30,59
A related limitation to all studies quantifying NAFLD at the
population level is the lack of consistent diagnostic measures.
Rates of NAFLD prevalence have been shown to vary between
studies with measures based on liver enzymes resulting in
lower estimates than imaging/histology10 and NASH can be his-
tologically detected in many NAFLD cases with normal liver
enzymes.62 While there is considerable uncertainty surrounding
NASH diagnosis (yes, no, or probable), staging of fibrosis alone
has been shown to be an effective predictor of long term out-
comes in NAFLD cases;63,64 and non-invasive tests are available
to predict advanced fibrosis, but still have not been approved for
this purpose.65 However, there is a need to better identify risk
factors for progression among early fibrosis cases.66 Also, age
is a confounding factor when using non-invasive prediction
models for advanced fibrosis, which could thus be underesti-
mated in patients aged ≥65 years.67 Finally, the analysis is based
on the change in obesity rates in each country, yet there are
examples of lean NAFLD. In these cases, NAFLD occurs in indi-
viduals with normal or low BMI. Lean NAFLD cases account
for a minority of total cases, and were not modeled separately.
The results of this analysis demonstrate a large and growing
burden of disease associated with NAFLD and NASH, in concert
with a global pandemic of obesity.68 The World Health Organi-
zation has called for efforts to halt the rise of diabetes and obe-
sity at the global level,69 with sustainable development goal 3.4
calling for a reduction by one-third in premature mortality from
non-communicable diseases by 2030 through prevention and
treatment. Efforts to mitigate disease burden are critical, and
should be linked to strategies that curb the growth of obesity
and DM at both the national and global levels.
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